Corbus Pharmaceuticals Holdings, Inc. CRBP
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $39.71 (+926.2% upside)
Key Stats
- Today's Range
- $3.73 – $4.11
- 50-Day Range
- $3.73 – $11.60
- 52-Week Range
- $3.73 – $20.56
- Volume
- 4.37 million shs
- Average Volume
- 1.02 million shs
- Market Cap
- $75.72 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 41.63%
- Days to Cover
- 13.65
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Related Stocks
Compare head-to-head: CRBP vs LLY·CRBP vs JNJ·CRBP vs ABBV·CRBP vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.